Cargando…
Use of Pembrolizumab in End-Stage Renal Disease: A Case Report with Complete Response
Second-line treatment in urothelial carcinoma is not well defined. Immunotherapy has shown good outcomes in this setting, but it has not been tested in patients with end-stage renal disease (ESRD). We present a clinical case describing the use of pembrolizumab in a patient under hemodialysis (HD) th...
Autores principales: | Vitorino, Marina, Santos, Catarina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958579/ https://www.ncbi.nlm.nih.gov/pubmed/35431871 http://dx.doi.org/10.1159/000521979 |
Ejemplares similares
-
Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
por: Kamei, Jun, et al.
Publicado: (2022) -
Pathological Complete Response of Metastatic Clear Cell Renal Carcinoma with Pembrolizumab and Axitinib: A Case Report and Review of Literature
por: Beirat, Amir F., et al.
Publicado: (2023) -
Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
por: Marcrom, Samuel, et al.
Publicado: (2017) -
Pembrolizumab for cutaneous squamous cell carcinoma: Report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation
por: van Baar, Mireille L.M., et al.
Publicado: (2019) -
Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report
por: Liu, Zhaonan, et al.
Publicado: (2019)